Serum Autotaxin is not a Useful Biomarker for Ovarian Cancer
Abstract
Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.Keywords
This publication has 18 references indexed in Scilit:
- Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cellsCellular Signalling, 2010
- Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphomaBritish Journal of Haematology, 2008
- Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activityAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2008
- Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer CellsMolecular Cancer Research, 2008
- Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiationClinica Chimica Acta, 2008
- Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis CJournal of Clinical Gastroenterology, 2007
- Measurement of lysophospholipase D/autotaxin activity in human serum samplesClinical Biochemistry, 2007
- GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5Journal of Biological Chemistry, 2006
- Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic CancersJAMA, 1998
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983